- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02035566
Telehome Monitoring for Chronic Disease Management
Effectiveness of Telehome Monitoring on Quality of Life and Health Resources Utilization Among People With Chronic Disease Residing in Rural Maryland
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
While the nation's overall health status has improved over the past decade, disparities persist among racial/ethnic minorities, low-income whites, the medically under-served, and rural residents. The disparities in disease morbidity and mortality are a compelling crisis and the elimination of such disparities is a national priority. With an aging population, the changing demographics are increasing the disease burden attributable to chronic diseases.
The broad goal of this project is to evaluate the potential value of using THC technology in chronically ill patients in rural Maryland, within the broad context of social determinants of health. This builds upon a completed pilot research study in Garrett County on a small scale THC program in rural Garrett County Maryland funded by the Maryland Cigarette Restitution Fund (CRF) supported Other Tobacco Related Diseases (OTRD grant) (CBaquet PI) in collaboration with the division of cardiology and department of family medicine. This research study will look at whether the THC equipment in the home for 60 days will make a difference in the health of the patients who get the unit in their home compared to the patients who will not receive the unit for 60 days. And we will look at whether this technology will support patient monitoring in the home. The use of the technology will be evaluated to determine whether patient monitoring using THC equipment will influence the hospitalization rates or emergency department visits for the patients. Evaluation of the influence of the THC equipment on medical resource utilization in rural and medically underserved communities will be studied.
Telehome care (THC) may provide augmentation to current face to face monitoring through home visits (usual method for Center for Medicaid and Medicare Services (CMS) billable home health services) of chronically ill patients and may provide an innovative and potentially cost-effective solution to improving patients' outcomes and health care resource utilization in rural areas. THC can support the coordination of care by assessing and monitoring patients in their homes and giving health care providers appropriate feedback to assure patient compliance with discharge instructions such as medication, home care and other aspects of recommended treatment regimens. Further, THC may improve service coordination at discharge and provide ongoing monitoring/engagement of patients, which is considered essential to prevent re-hospitalizations and emergency department visits. Demonstration of the potential benefits on care pathways, and patient and provider acceptance and satisfaction with the technology requires systematic larger scale and scientifically rigorous studies.
Purpose The project's broad goals are to evaluate the effects of telehome care (THC), a form of remote patient home monitoring,(within the broad context of social determinants of health) for chronic disease management among rural residing minority, low-income white, and medically underserved patients by: (a) providing an innovative telehome care (THC) capacity and infrastructure in two Maryland rural and medically underserved communities; and (b) using the THC infrastructure to generate scientifically rigorous and high quality evidence on whether the THC technology improves patient monitoring, influences clinical outcomes, and has an impact on medical resource utilization. [NOTE: THC uses telecommunication technologies to enable home health agency clinical staff at a rural home health agency to monitor their patients in the home.]
The major aim for this study are: 1) To evaluate the impact of the 60-day in home THC monitoring on medical resource utilization (emergency department visits; re-hospitalization rates) and Quality of Life related to the management of Metabolic Syndrome/Diabetes Mellitus (DM), Chronic Heart Failure (CHF), Hypertension (HTN), and Chronic Obstructive Pulmonary Disease (COPD) compared to those patients that receive only an educational pamphlet. Secondary aim hopes to support patient education to enhance acceptability, patient independence and satisfaction.
In this study, remote in-home patient monitoring using a THC system from VitelNet (telehealth equipment vendor) will provide patient monitoring remotely or non billable services for the experimental study arm for this project in addition to routine billable home health services. This project does not substitute billable in-home monitoring of patients which is a prerequisite for enrollment into this study(conventional home health services) but provides remote monitoring for the study arm in addition to conventional/billable services delivered.
Patients are randomized to either THC use for 60 days with 60, 90 day follow up or "usual care" with 60, 90 day follow up.
In addition, new knowledge will be generated by this study on methods for conduct of health disparities research and training of non-research clinical personnel who are community based in data collection and research ethics.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Maryland
-
Hughesville, Maryland, Spojené státy, 20637
- Chesapeake-Potomac Home Health Agency
-
Oakland, Maryland, Spojené státy, 21550
- Garrett County Health Department Home Health Agency
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Home bound at a home health agency (i.e., Garrett County Health Department Home Health Agency or Chesapeake-Potomac Home Health Agency)
- Clinical diagnosis of at least one of the following: chronic obstructive pulmonary disease, chronic heart failure, uncontrolled hypertension, diabetes mellitus and taking anti-hyperglycemic oral therapy
- Able to operate the telehome care system
- Agreeable to have the telehome care system installed at residence for 60 days
- Residing in an environment where care can be provided safely
Exclusion Criteria:
- Not eligible for home health care
- With a clinical diagnosis of a medical condition other than obstructive pulmonary disease, chronic heart failure, uncontrolled hypertension, diabetes mellitus and taking anti-hyperglycemic oral therapy
- Unable to follow instructions about or be able to operate the telehome care system
- Residing in an environment that is unsafe to provide home health care
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Obvyklá péče
|
|
|
Experimentální: Telehome Care Monitoring + Usual Care
|
Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Self reported Quality of life
Časové okno: The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day evaluated.
|
The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
|
Number of emergency department visits
Časové okno: The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day post baseline for:
|
The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
|
Re-hospitalization
Časové okno: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day post baseline for:
|
Assessing change from baseline and 90-day post-baseline
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of contacts (visits or phone calls) with health care providers
Časové okno: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline and 90-day post-baseline
|
|
|
Adequacy of hypertension control
Časové okno: Measures change from baseline and 90-day post-baseline
|
Measures change from baseline to 90 day post baseline for:adequacy of blood pressure control (<140/90 mmHg)
|
Measures change from baseline and 90-day post-baseline
|
|
Adequacy of diabetes control
Časové okno: Measures change from baseline and 90-day post-baseline
|
adequacy of glycemic control of HbA1C of <7.5
|
Measures change from baseline and 90-day post-baseline
|
|
Compliance with recommended (by discharging physician/primary health professional) drug therapy use for heart failure
Časové okno: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline and 90-day post-baseline
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Claudia R Baquet, MD MPH, University of Maryland School of Medicine
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- HP-00044150
- RC2MD004800 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Srdeční selhání
-
Region SkaneZápis na pozvánkuSrdeční selhání New York Heart Association (NYHA) třída II | Srdeční selhání New York Heart Association (NYHA) třída IIIŠvédsko
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... a další spolupracovníciUkončenoSrdeční selhání, systolické | Srdeční Selhání Se Sníženou Ejekční frakcí | Srdeční selhání New York Heart Association Třída IV | Srdeční selhání New York Heart Association Třída IIIPolsko
-
Novartis PharmaceuticalsDokončenoPacienti, kteří úspěšně dokončili 12měsíční léčebné období základní studie (de Novo Heart Recipients), kteří měli zájem o léčbu EC-MPS
-
University of WashingtonAmerican Heart AssociationDokončenoSrdeční selhání, městnavé | Mitochondriální alterace | Srdeční selhání New York Heart Association Třída IVSpojené státy
-
Portuguese Association of Interventional CardiologyMedtronicNáborTěžká symptomatická aortální stenóza (definována jako třída New York Heart Association (NYHA) ≥ II)Portugalsko
Klinické studie na Telehome Care Monitoring
-
Ascensia Diabetes CareDokončeno
-
University of PennsylvaniaDokončeno
-
Biotronik SE & Co. KGDokončenoFibrilace komor | Ventrikulární tachykardie | Městnavé srdeční selháníDánsko, Německo, Izrael, Austrálie, Rakousko, Česká republika, Lotyšsko
-
Assiut UniversityZatím nenabírámePředčasný ventrikulární komplex
-
Insel Gruppe AG, University Hospital BernUkončeno
-
Yuksek Ihtisas UniversityDokončenoPandemie covid-19Krocan
-
University of PennsylvaniaNational Institute of Nursing Research (NINR)DokončenoSrdeční selháníSpojené státy
-
Abbott Medical DevicesDokončenoLéčba městnavého srdečního selháníItálie
-
Indiana UniversityUniversity of Notre Dame; Elevate Ventures; NearWave Corp.NáborRakovina prsu | HER2-pozitivní rakovina prsu | Invazivní karcinom prsu | HER2-negativní rakovina prsu | TNBC - Triple-negativní rakovina prsuSpojené státy
-
Ottawa Heart Institute Research CorporationDokončeno